🔥🐔 BizChicken 🐔🔥
Learn About the Corporations Around You
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Atea Pharmaceuticals, Inc.
Market Cap: Low
Employees: Low
AT-527
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a lead product candidate AT-527 for COVID-19 treatment.
Symbol: AVIR
Recent Price: $3.33
Industry: Biotechnology
CEO: Dr. Jean-Pierre Sommadossi Ph.D.
Sector: Healthcare
Employees: 75
Address: 125 Summer Street, Boston, MA 02110
Phone: 857 284 8891
Leadership
- Jean-Pierre Sommadossi, PhD, FOUNDER, CHAIRMAN & CEO
- Nancy Agrawal, PhD, Executive VP, Preclinical Development
- Jonae Barnes, Senior VP, Investor Relations & Corporate Communications
- Bruce Belanger, PhD, Senior VP, Biostatistics
- Andrea Corcoran, CFO & Executive VP, Legal
- Adam DeZure, MD, VP, Clinical Development
- James MB Evans, PhD, VP, CMC Manufacturing
- Wayne Foster, EXECUTIVE VP, Chief Accounting Officer
- Kerry Gagnon, VP, Head of Quality
- Steven Good, EXECUTIVE VP, PRECLINICAL SCIENCE
- Janet Hammond, MD, PhD, CHIEF DEVELOPMENT OFFICER
- Arantxa Horga, MD, Chief Medical Officer
- Qi Huang, Senior VP, Virology
- Laura Ishak, Senior VP, Clinical Operations
- Ariyapadi Krishnaraj, VP, Marketing
- Adel Moussa, PhD, EXECUTIVE VP, CHEMISTRY
- Shari Noble, VP, Deputy General Counsel
- Keith Pietropaolo, Executive VP, Clinical Sciences and Project Management
- Brian Rowe, VP, Business Development
- Marc Van Hulle, VP, Finance
- John Vavricka, CHIEF COMMERCIAL OFFICER
- Alex Vo, PhD, VP, DMPK
- Jayanthi Wolf, PhD, Executive VP, Regulatory Affairs
- Xiao-Jian Zhou, PhD, EXECUTIVE VP, EARLY STAGE DEVELOPMENT
Last updated: 2024-12-31